中医药治疗慢性心力衰竭临床疗效评价与思考
Evaluation and consideration of the curative effects of traditional Chinese medicine in the treatment of chronic heart failure
- 北京中医药大学学报 2023年46卷第7期 页码：902-907
- 作者机构：
河南中医药大学第一附属医院 郑州 450046
- 作者简介：
Prof. ZHU Mingjun, Ph. D., Chief Physician, Doctoral Supervisor. The First Affiliated Hospital of Henan University of Chinese Medicine, No.19, Renmin Road, Jinshui District, Zhengzhou 450046. E-mail: zhumingjun317@163.com
- 基金信息：国家重点研发计划项目(2019YFC1710000);国家自然科学基金项目(82074226;82030120)
DOI：10.3969/j.issn.1006-2157.2023.07.003
中图分类号： R259.416纸质出版日期：2023-07-30，
网络出版日期：2023-05-26，
收稿日期：2022-12-26，
- 稿件说明：
移动端阅览
朱明军. 中医药治疗慢性心力衰竭临床疗效评价与思考[J]. 北京中医药大学学报, 2023,46(7):902-907.
ZHU Mingjun. Evaluation and consideration of the curative effects of traditional Chinese medicine in the treatment of chronic heart failure[J]. Journal of Beijing University of Traditional Chinese Medicine, 2023,46(7):902-907.
朱明军. 中医药治疗慢性心力衰竭临床疗效评价与思考[J]. 北京中医药大学学报, 2023,46(7):902-907. DOI： 10.3969/j.issn.1006-2157.2023.07.003.
ZHU Mingjun. Evaluation and consideration of the curative effects of traditional Chinese medicine in the treatment of chronic heart failure[J]. Journal of Beijing University of Traditional Chinese Medicine, 2023,46(7):902-907. DOI： 10.3969/j.issn.1006-2157.2023.07.003.
摘要
中医临床疗效评价是目前中医学发展的热点，受到广泛的关注，科学、恰当地选择中医药防治慢性心力衰竭的疗效和安全性评价指标是本病临床疗效评价研究的难点。经过文献研究，本文将中医药治疗慢性心力衰竭的结局指标分为远期预后、客观检查指标、症状体征、生活质量、运动耐量、卫生经济学评估及安全性评价7个类别，并论述了其研究现状。研究发现，当前中医药治疗慢性心力衰竭结局指标的选择存在评价指标种类多样，无统一、规范的推荐选择标准，多个结局指标罗列，未能明确区分主要与次要结局指标，未能重视结局指标和生活质量评价，缺乏统一的中医临床疗效评价工具等多个问题。因此，需要建立统一、规范的慢性心力衰竭中医临床疗效评价工具，建立临床研究结局指标的选择与应用标准，并开展以结局指标为主要评价指标的高质量中医药治疗心力衰竭的临床研究，以获得国际认可的中医药循证医学证据。
Abstract
Evaluation of the clinical efficacy of traditional Chinese medicine (TCM) is a research hotspot in the development of TCM and an issue of widespread concern. Scientifically and appropriately selecting indicators to evaluate the efficacy and safety of TCM in the prevention and treatment of chronic heart failure is difficult. In this paper
the outcome indicators of TCM for chronic heart failure are divided into seven categories: long-term prognosis
objective inspection
symptoms and signs
quality of life
exercise tolerance
health economics
and safety. The current research status is also discussed. It is found that there are various types of outcome indicators to evaluate the treatment of chronic heart failure with TCM
and there are no unified and standardized recommended selection criteria
due to factors including the failure to clearly distinguish between primary and secondary efficacy indicators
failure to pay attention to outcome indicators and evaluate quality of life
and the lack of a unified TCM efficacy evaluation tool for symptoms. Therefore
it is necessary to establish a unified and standardized tool to evaluate the efficacy of TCM treatment of chronic heart failure
and the selection and application of standards for clinical research outcome indicators.This is necessary to perform high-quality clinical research on TCM treatment of heart failure with outcome indicator as the main evaluation indicator
and obtain internationally recognized evidence-based support for TCM.
关键词
慢性心力衰竭疗效评价结局指标中医证候
Keywords
chronic heart failureefficacy evaluationoutcome indicatorssyndrome of traditional Chinese medicine
references
中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志，2018, 46(10): 760-789.
国家心血管病医疗质量控制中心专家委员会心力衰竭专家工作组. 2020中国心力衰竭医疗质量控制报告[J]. 中国循环杂志，2021, 36(3): 221-238.
HAO G, WANG X, CHEN Z，et al.Prevalence of heart failure and left ventricular dysfunction in China：the China Hypertension Survey, 2012－2015[J].Eur J Heart Fail，2019，21(11):1329-1337.
JONES NR, ROALFE AK, ADOKI I，et al.Survival of patients with chronic heart failure in the community：a systematic review and meta-analysis[J].Eur J Heart Fail，2019，21(11):1306-1325.
WANG H, CHAI K, DU MH，et al. Prevalence and Incidence of Heart Failure Among Urban Patients in China：A National Population-Based Analysis[J/OL]. Circ Heart Fail，2021，14(10):e008406 [2022-12-10]. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008406.
孙龙飞，安冬青，郭龙龙. 心力衰竭的中医药治疗优势与特色[J]. 中国中医急症，2016, 25(3): 452-456.
刘保延. 中医临床疗效评价研究的现状与展望[J]. 中国科学基金，2010, 24(5): 268-274.
李静．临床试验设计：随机对照[J].中国循环杂志，2017，32(11):1126-1127.
CLARKE M, WILLIAMSON P. Core outcome sets and trial registries[J/OL]. Trials, 2015, 16: 216 [2022-12-10]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446826/.
代欣玥，訾明杰，杨巧宁，等．基于文献的中医药临床研究结局指标现状分析及思考[J].中医杂志，2022，63(12):1122-1127.
吴大嵘. 中医临床疗效评价基础性问题思考[J]. 中国中西医结合杂志，2011, 31(4): 445-458.
孙亚男，刘雅莉，郭俊明，等．体现中医药干预特色的结局指标集的构建[J].中医杂志，2021，62(13):1134-1137.
食品药品监管总局. 总局关于发布中药新药用于肠易激综合征临床研究技术指导原则等5个临床研究技术指导原则的通告(2017年第217号)[EB/OL].(2017-12-27)[2022-12-10]. https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20171227183101142.html.
李慧敏，熊兴江，赵晖，等. 中医药治疗慢性心力衰竭随机对照试验结局指标的现状分析[J]. 中华中医药杂志，2022, 37(3): 1750-1757.
HEIDENREICH PA, BOZKURT B, AGUILAR D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J/OL]. Circulation，2022，145(18):e895-e1032[2022-12-10]. https://doi.org/10.1161/CIR.0000000000001063.
MCMURRAY JJV, SOLOMON SD, INZUCCHI SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction[J]. N Engl J Med, 2019，381(21):1995-2008.
PACKER M, ANKER SD, BUTLER J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure[J]. N Engl J Med, 2020，383(15):1413-1424.
ANKER SD, BUTLER J, FILIPPATOS G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction[J]. N Engl J Med, 2021，385(16):1451-1461.
SOLOMON SD, SKALI H, ANAVEKAR NS, et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction[J]. Circulation，2005，111(25):3411-3419.
卫靖靖，朱明军，王永霞，等．心脉隆注射液治疗冠心病心力衰竭有效性与安全性的系统评价[J].中国中药杂志，2020，45(19):4756-4765.
卫靖靖，李彬，朱明军，等．参麦注射液治疗急性心肌梗死后心力衰竭的系统分析和试验序贯分析[J].中国医院药学杂志，2021，41(20):2082-2090.
LIU CF, FERRARI VA, HAN YC. Cardiovascular Magnetic Resonance Imaging and Heart Failure[J/OL]. Curr Cardiol Rep，2021，23(4):35[2022-12-10]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939452/.
SAMMAN TAHHAN A, VADUGANATHAN M, GREENE SJ, et al. Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment[J]. Curr Heart Fail Rep, 2018，15(1):10-16.
JANUZZI JL, AHMAD T, MULDER H, et al. Natriuretic peptide response and outcomes in chronic heart failure with reduced ejection fraction[J]. J Am Coll Cardiol, 2019, 74(9): 1205-1217.
LI XL, ZHANG J, HUANG YJ. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin Capsules in patients with chronic heart failure[J]. J Am Coll Cardiol, 2013, 62(12): 1066-1072.
DEBOER RA, LOK DJ, JAARSMA T, et al. Predictive value of plasma galectin－3 levels in heart failure with reduced and preserved ejection fraction[J]. Ann Med, 2011, 43(1): 60-68.
BROCH K, UELAND T, NYMO SH, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology[J]. Eur J Heart Fail, 2012, 14(3): 268-277.
WANG TJ, WOLLERT KC, LARSON MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress：The framingham heart study[J]. Circulation, 2012, 126(13): 1596-1604.
ZANNAD F, GARCIA AA, ANKER SD, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document [J]. Eur J Heart Fail, 2013, 15(10):1082-1094.
The Criteria Committee of the New York Heart Association.1994 revisions to classification of functional capacity and objective assessment of patients with disease of the heart[J].Circulation，1994，90:644-645.
吕美君，张会永，陈智慧，等. 基于MYMOP探讨以患者主诉症状为主体的中医证候疗效评价方法构建[J]. 中华中医药学刊，2020, 38(2): 62-64.
朱明军，王永霞，李彬，等. 参附益心颗粒辨证联合西药治疗慢性心力衰竭的多中心、随机、双盲、安慰剂对照研究[J]. 中医杂志，2019, 60(21): 1843-1848.
HOEKSTRA T, JAARSMA T, VAN VELDHUISEN DJ, et al. Quality of life and survival in patients with heart failure[J]. Eur J Heart Fail, 2013，15(1):94-102.
赵志强，王贤良，张萍，等. 养阴舒心方对射血分数正常心力衰竭患者生存质量的影响[J]. 中医杂志，2018, 59(21): 1843-1847.
TUCKER WJ, HAYKOWSKY MJ, SEO Y, et al. Impaired Exercise Tolerance in Heart Failure: Role of Skeletal Muscle Morphology and Function[J]. Curr Heart Fail Rep, 2018，15(6):323-331.
GUAZZI M, ARENA R, HALLE M, et al. 2016 focused update：Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations[J]. Circulation, 2016, 133(24): 694-711.
王艳敏，王露，刘岢，等. 益气温阳中药提高心力衰竭患者运动耐量的作用研究[J]. 中国中医急症，2021, 30(12): 2186-2188.
俞达，蒋朱秀. 太极拳和八段锦对慢性心力衰竭患者运动耐量和生活质量的影响[J]. 新中医，2019, 51(3): 274-277.
柳鸿鹏，吴欣娟. 国外卫生经济学评价的研究进展[J]. 中华现代护理杂志，2020, 26(24): 3394-3397.
心脉隆注射液临床研究协作组. 心脉隆注射液治疗射血分数降低的心力衰竭的药物经济学评价[J]. 中华心力衰竭和心肌病杂志，2020, 4(3): 191-196.
范琦琦，李芝奇，陈美琳，等. 基于斑马鱼模型的中药安全性评价研究进展[J]. 中草药，2022, 53(1): 278-287.
郭新峰，赖世隆，梁伟雄．中医药临床疗效评价中结局指标的选择与应用[J].广州中医药大学学报，2002，19(4):251-255.
姚久秀，戴国华，赵雪. 中医药治疗慢性心力衰竭疗效评价指标文献分析[J]. 山东中医药大学学报，2021, 45(6): 782-787.
LEVIN JS, GLASS TA, KUSHI LH, et al. Quantitative methods in research on complementary and alter native medicine: A methodological manifesto[J]. Med Care, 1997, 35(11): 1079-1094.
戴亮，郑颂华，田然，等. 规范中医药临床研究方案内容2018声明：建议、说明与详述[J].中国中西医结合杂志，2019, 39(6): 739-749.
《中成药治疗优势病种临床应用指南》标准化项目组. 中成药治疗心力衰竭临床应用指南(2021年) [J]. 中国中西医结合杂志，2022, 42(3): 261-275.
0
浏览量
92
下载量
1
CSCD
- 网络PDF下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 地址：北京市朝阳区北三环东路11号 邮编：100029
- 联系电话：(010)53911857 Email：jbutcm@bucm.edu.cn
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies